Início › Leucemia Mieloide Aguda › Missouri
Ensaios clínicos de Leucemia Mieloide Aguda em Missouri
23 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Missouri.
Cidades em Missouri
Texto oficial do estudo (Inglês)
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Washington University /ID# 280295, St Louis
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- e mais 21
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- e mais 2
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- e mais 2
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Washington University in St Louis, St Louis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Parkland Health Center - Farmington, Farmington
- e mais 10
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- e mais 2
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- e mais 2
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Washington University in St. Louis School of Medicine, St Louis
RecrutandoFase 1/2
30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Washington University in St. Louis, St Louis
RecrutandoEstudo observacional
Idades 0 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07154823Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-St Louis MO-WASHU, St Louis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT07223814Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Washington University in St Louis, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- e mais 2
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Washington University School of Medicine, St Louis
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06158828Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- The Children's Mercy Hospital - Adele Hall Campus, Kansas City
- Washington University School of Medicine in St. Louis, St Louis
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Washington University School of Medicine, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT06001788Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Washington University, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06529731Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Mercy Hospital of Kansas City, Kansas City
RecrutandoFase 1
Idades de 1 a 30 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06177067Motixafortide for MRD Sensitization in AML
- Washington University School of Medicine, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de jul. de 2026 · NCT07392970A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Mercy Hospital and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University St. Louis, St Louis
- e mais 1
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Washington University in St. Louis, St Louis
RecrutandoFase 1
Idades 12 e acima · Todos os sexos · Atualizado em 16 de mar. de 2026 · NCT06994676Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- Washington University School of Medicine, St Louis
RecrutandoVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 16 de out. de 2025 · NCT04986657Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.